A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.

Completed · Phase 4

Conditions studied: Urinary Bladder, Overactive

In brief

The purpose of this study is to evaluate the efficacy and safety of tolterodine in impacting the primary symptom or complaint of patients with OAB.

Key facts

Study ID

NCT00645281

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

896

Starts

2004-03-01

Expected to finish

2005-01-01

Last updated by the study team

2021-01-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• self-reported symptoms of OAB for ≥ 3 months prior to screening
• OAB as defined by urinary frequency (a minimum of 8 micturitions per 24 hours)
• urgency (defined as a strong and sudden desire to urinate) or urge incontinence a minimum of 2 episodes in 3 days, as confirmed by the micturition diary between screening and baseline
• patients who describe the degree of bothersomeness of their most bothersome OAB symptom as "moderately ", "a great deal ", or "a very great deal" per the OAB Bother Rating Scale

You may not qualify if…

• any condition that would contraindicate their usage of tolterodine once daily, including: narrow angle glaucoma, urinary retention, gastric retention
• any clinically significant local urinary tract pathology which could mimic the symptoms of OAB, such as infection or hematuria
• stress incontinence, functional, or overflow incontinence as determined by the investigator
• symptomatic acute urinary tract infection (UTI) during the run-in period, or recurrent UTIs defined by treatment for symptomatic UTI >3 times in the 12 months prior to participation in this clinical trial
• clinically significant urinary tract obstruction
• history of lower urinary tract surgery (e.g. prostate removal or destruction, incontinence surgery) within the past 3 months
• clinically significant interstitial cystitis or significant bladder pain syndrome

Where it is running

• Pfizer Investigational Site — Birmingham, Alabama, United States
• Pfizer Investigational Site — Birmingham, Alabama, United States
• Pfizer Investigational Site — Huntsville, Alabama, United States
• Pfizer Investigational Site — Montgomery, Alabama, United States
• Pfizer Investigational Site — Phoenix, Arizona, United States
• Pfizer Investigational Site — Sun Lakes, Arizona, United States
• Pfizer Investigational Site — Bentonville, Arkansas, United States
• Pfizer Investigational Site — Jonesboro, Arkansas, United States
• Pfizer Investigational Site — Little Rock, Arkansas, United States
• Pfizer Investigational Site — Buena Park, California, United States
• Pfizer Investigational Site — Foothill Ranch, California, United States
• Pfizer Investigational Site — Fresno, California, United States
• Pfizer Investigational Site — West Covina, California, United States
• Pfizer Investigational Site — Colorado Springs, Colorado, United States
• Pfizer Investigational Site — Lakewood, Colorado, United States
• Pfizer Investigational Site — Chipley, Florida, United States
• Pfizer Investigational Site — Davie, Florida, United States
• Pfizer Investigational Site — Hallandale, Florida, United States
• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Miami Beach, Florida, United States
• Pfizer Investigational Site — Murdock, Florida, United States
• Pfizer Investigational Site — Ocala, Florida, United States
• Pfizer Investigational Site — Pembroke Pines, Florida, United States
• Pfizer Investigational Site — Saint Cloud, Florida, United States
• Pfizer Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.